Therapeutics News and Research

RSS

Multiple cell and gene therapies can enhance cardiac function in mice modeled with MI

Researchers at the University of Utah compared the therapeutic potential of umbilical cord-derived sub-epithelial cells (UC-SECs), bone marrow-derived mesenchymal stem cells (BM-MSCs) and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) -- all derived from human tissue -- along with genes (S100a1 and SDF-1a) and growth factor (VEGF165) to evaluate how injected biologics might enhance cardiac function in mice modeled with myocardial infarction (MI; commonly referred to as heart attack).

2 Jun 2016

Study provides new insights into molecular basis of CaSR-related human diseases

A study led by researchers at Georgia State University provides new insights into the molecular basis of human diseases resulting from mutations in the calcium-sensing receptor (CaSR), a protein found in cell membranes.

1 Jun 2016

University of Leicester researcher awarded grant to develop bacteriophages to target infant Shigella

A University of Leicester researcher has been awarded funding to develop bacteriophages to target bacterial infant diarrhoea in the developing world where it causes significant mortality.

28 May 2016

New, simpler way for encapsulation-free controlled protein release

A U of T Engineering team has designed a simpler way to keep therapeutic proteins where they are needed for long periods of time. The discovery is a potential game-changer for the treatment of chronic illnesses or injuries that often require multiple injections or daily pills.

28 May 2016

External stimulation guides brain circuit’s early development

A healthy brain has just the right ratio of cells that enhance signals (excitatory neurons) and cells that tone down signals (inhibitory neurons). These two sets of neurons start out looking exactly the same, so what determines their roles?

27 May 2016

TSRI scientists discover new method for harnessing venoms for therapeutic use

There are lessons to be learned from venoms. Scorpions, snakes, snails, frogs and other creatures are thought to produce tens or even hundreds of millions of distinct venoms. These venoms have been honed to strike specific targets in the body.

26 May 2016

Automated Liquid Handling in Pharmaceutical Research

In this interview, News Medical talks to Dr. Alfred Chappell of Ionis Pharmaceuticals about automated liquid handling in pharmaceutical research.

From Beckman Coulter Life Sciences - Automation and Genomics 26 May 2016

Study provides better understanding of sequence of genetic events in colorectal cancer premalignancy

Whole-exome sequencing of both colorectal adenomas (precancers often called polyps) and intestinal mucosa at risk for developing into adenomas from patients with familial adenomatous polyposis (FAP) has generated a comprehensive picture of the genomic alterations that characterize the evolution of normal mucosa to precancer.

25 May 2016

Purdue researchers find potential way to overcome limitations posed by CAR T-cell therapy

Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."

24 May 2016

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

23 May 2016

Small lipid nanocarrier may deliver chemotherapeutic drug more efficiently to brain tumor cells

Great discoveries do come in small packages. Few know that better than Ann-Marie Broome, Ph.D., who feels nanotechnology holds the future of medicine with its ability to deliver powerful drugs in tiny, designer packages.

23 May 2016

Understanding potential of illicit drug ketamine in treating depression

Advancing the understanding and treatment of psychiatric disorders is a principal goal of neuroscientists. As mental disorders are the leading cause of disabilities worldwide, it is concerning that there are few effective therapeutics on the market due to the lack of knowledge regarding pathophysiology.

19 May 2016

Understanding antibody transport mechanisms in the brain

Diseases of the central nervous system (CNS), such as stroke, brain cancer, and Alzheimer's disease, are a serious threat affecting over 50 million Americans with an associated cost of over $750 billion per year, which is expected to grow significantly over the coming decades.

19 May 2016

Basic mechanisms behind memory are more dynamic, research finds

We tend to think our memory works like a filing cabinet. We experience an event, generate a memory and then file it away for later use. However, according to medical research, the basic mechanisms behind memory are much more dynamic.

18 May 2016

Insulin pump therapy can benefit all type 1 diabetes patients

Insulin pump therapy contributes to better blood glucose control in type 1 diabetes and, as pump technology continues to improve and become part of sensor-controlled feedback and artificial pancreas systems, essentially all patients would benefit from their capabilities according to a Commentary published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

18 May 2016

Ipsen partners with IMCB to advance understanding and research of Botulinum Neurotoxin Biology

Ipsen S.A., a global specialty-driven pharmaceutical company, and the Institute of Molecular and Cell Biology (IMCB), a research institute under the aegis of the Agency for Science, Technology and Research (A*STAR), Singapore, today announced the signature of a research partnership to study the intracellular trafficking of botulinum neurotoxins (BoNTs) within neurons.

16 May 2016

Pluristem completes enrollment in Phase II intermittent claudication trial

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.

16 May 2016

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos Therapeutics, Inc., a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in distribution channels and is now available to prescribe for patients with ADHD in the United States.

16 May 2016

Unlocking the dark proteome: an interview with Dr Kriwacki

The term dark proteome refers to proteins whose structural features and thus functions are not well understood. Many proteins within the dark proteome do not fold into stable three-dimensional structures. These proteins are called intrinsically disordered proteins (IDPs) and feature highly flexible, disordered confirmations.

16 May 2016

Combination of COX-2-selective NSAID with PPI can reduce risk of stomach, intestinal ulcers

Non-steroidal anti-inflammatory drugs (NSAIDs)—including ibuprofen, diclofenac, naproxen and others—are commonly used pain medications that are generally safe but may increase the risk of developing stomach and intestinal ulcers.

13 May 2016

Therapeutics News and Research

Multiple cell and gene therapies can enhance cardiac function in mice modeled with MI

Study provides new insights into molecular basis of CaSR-related human diseases

University of Leicester researcher awarded grant to develop bacteriophages to target infant Shigella

New, simpler way for encapsulation-free controlled protein release

External stimulation guides brain circuit’s early development

TSRI scientists discover new method for harnessing venoms for therapeutic use

Automated Liquid Handling in Pharmaceutical Research

Study provides better understanding of sequence of genetic events in colorectal cancer premalignancy

Purdue researchers find potential way to overcome limitations posed by CAR T-cell therapy

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

Small lipid nanocarrier may deliver chemotherapeutic drug more efficiently to brain tumor cells

Understanding potential of illicit drug ketamine in treating depression

Understanding antibody transport mechanisms in the brain

Basic mechanisms behind memory are more dynamic, research finds

Insulin pump therapy can benefit all type 1 diabetes patients

Ipsen partners with IMCB to advance understanding and research of Botulinum Neurotoxin Biology

Pluristem completes enrollment in Phase II intermittent claudication trial

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Unlocking the dark proteome: an interview with Dr Kriwacki

Combination of COX-2-selective NSAID with PPI can reduce risk of stomach, intestinal ulcers

Industry Focus eBook - Biotechnology (4th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News